Prokidney (PROK) Shares Outstanding (Diluted Average) (2021 - 2026)
Prokidney (PROK) reported Shares Outstanding (Diluted Average) of $141.9 million for Q1 2026, up 11.77% year-over-year from $127.0 million in Q1 2025, and up 5.96% on a QoQ basis from $133.9 million in Q4 2025.
Prokidney (PROK) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $141.9 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) rose 11.77% year-over-year to $141.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.9 million (up 11.77% YoY) and the FY2025 annual result came in at $133.9 million, up 36.79% from the prior year.
- Shares Outstanding (Diluted Average) advanced to $141.9 million in Q1 2026 per PROK's latest filing, from $133.9 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $141.9 million in Q1 2026 and bottomed at $25.6 million in Q2 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $70.2 million (2023), against an average of $86.8 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) jumped 366.18%; it then decreased 0.96% in 2024.
- Tracing PROK's Shares Outstanding (Diluted Average) over 5 years: stood at $61.5 million in 2022, then rose by 0.28% to $61.7 million in 2023, then soared by 58.66% to $97.9 million in 2024, then soared by 36.79% to $133.9 million in 2025, then climbed by 5.96% to $141.9 million in 2026.
- Per Business Quant, the three latest PROK Shares Outstanding (Diluted Average) figures stand at $141.9 million (Q1 2026), $133.9 million (Q4 2025), and $135.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | 141.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 141.93 Mn |
| Dec 31, 2025 | 133.94 Mn |
| Sep 30, 2025 | 134.99 Mn |
| Jun 30, 2025 | 130.73 Mn |
| Mar 31, 2025 | 128.98 Mn |
| Dec 31, 2024 | 97.92 Mn |
| Sep 30, 2024 | 87.82 Mn |
| Jun 30, 2024 | 68.43 Mn |
| Mar 31, 2024 | 60.95 Mn |
| Dec 31, 2023 | 61.71 Mn |
| Sep 30, 2023 | 61.59 Mn |
| Jun 30, 2023 | 64.55 Mn |
| Mar 31, 2023 | 61.54 Mn |
| Dec 31, 2022 | 61.54 Mn |
| Sep 30, 2022 | 61.54 Mn |
| Jun 30, 2022 | 25.64 Mn |
| Jun 30, 2021 | 5.50 Mn |